Camille Bourreau

Prognostic Value and Relation with Adjuvant Treatment Duration of ctDNA in Stage III Colon Cancer: a <i>Post Hoc</i> Analysis of the PRODIGE-GERCOR IDEA-France Trial

Valérie Taly, Julie Henriques, Camille Bourreau et al. · Clinical Cancer Research · 2021 · 99 citations · Full text

Medicine, Molecular Medicine, Oncology +17

Analysis of circulating tumour DNA (ctDNA) from patients enrolled in the IDEA-FRANCE phase III trial: Prognostic and predictive value for adjuvant treatment duration

Valérie Taly, Déwi Vernerey, Camille Bourreau et al. · Annals of Oncology · 2019 · 65 citations · Full text

Medicine, Molecular Medicine, Oncology +16

Circulating Tumor DNA is Prognostic and Potentially Predictive of Eryaspase Efficacy in Second-line in Patients with Advanced Pancreatic Adenocarcinoma

Jean‐Baptiste Bachet, Hélène Blons, Pascal Hammel et al. · Clinical Cancer Research · 2020 · 39 citations · Full text

Medicine, Molecular Medicine, Oncology +17

Highly Specific Droplet-Digital PCR Detection of Universally Methylated Circulating Tumor DNA in Endometrial Carcinoma

Guillaume Beinse, Bruno Borghese, Marie Métairie et al. · Clinical Chemistry · 2022 · 29 citations · Full text

Medicine, Molecular Biology, Oncology +17

Early ctDNA and Survival in Metastatic Colorectal Cancer Treated With Immune Checkpoint Inhibitors

Francesco Giulio Sullo, Aurélie Lecanu, Camille Bourreau et al. · JAMA Oncology · 2025 · 18 citations · Full text

Medicine, Molecular Medicine, Oncology +17